J. Goldman & Co’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.6M | Sell |
84,235
-13,316
| -14% | -$1.67M | 0.25% | 102 |
|
|
2025
Q1 | $10.8M | Buy |
97,551
+51,825
| +113% | +$5.73M | 0.27% | 89 |
|
|
2024
Q4 | $6.24M | Buy |
+45,726
| New | +$6.24M | 0.16% | 141 |
|
|
2024
Q3 | – | Sell |
-35,721
| Closed | -$4.92M | – | 427 |
|
|
2024
Q2 | $4.92M | Buy |
35,721
+15,819
| +79% | +$2.18M | 0.14% | 126 |
|
|
2024
Q1 | $2.74M | Buy |
+19,902
| New | +$2.74M | 0.09% | 134 |
|
|
2023
Q4 | – | Sell |
-79,885
| Closed | -$8.99M | – | 302 |
|
|
2023
Q3 | $8.99M | Sell |
79,885
-5,489
| -6% | -$618K | 0.31% | 69 |
|
|
2023
Q2 | $8.05M | Buy |
85,374
+76,652
| +879% | +$7.23M | 0.29% | 70 |
|
|
2023
Q1 | $883K | Buy |
+8,722
| New | +$883K | 0.04% | 167 |
|
|
2022
Q4 | – | Sell |
-45,413
| Closed | -$4.82M | – | 333 |
|
|
2022
Q3 | $4.82M | Buy |
45,413
+37,831
| +499% | +$4.02M | 0.23% | 80 |
|
|
2022
Q2 | $739K | Buy |
+7,582
| New | +$739K | 0.04% | 186 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 301 |
|
|
2017
Q2 | – | Sell |
-46,700
| Closed | -$2.02M | – | 266 |
|
|
2017
Q1 | $2.02M | Buy |
+46,700
| New | +$2.02M | 0.1% | 117 |
|